A P-based repair and anti-aging composition, its preparation method and application

Abstract

This invention relates to the field of cosmetic technology, particularly to IPC A61K8, and more specifically to a substance P-based repair and anti-aging composition, its preparation method, and its application. The composition of this invention, by weight percentage, comprises 0.00003–0.3% peptides, 0.001–0.01% artemia extract, 0.0001–0.003% plant extracts, with the balance being solvent. This invention provides a multi-repairing composition for oily skin experiencing inflammatory aging caused by neurotransmitters. Through the compounding of active ingredients, a safe, effective, and stable formulation with a feasible process for large-scale production is prepared, providing users with a more comprehensive skincare solution.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, particularly to IPC A61K8, and more specifically to a substance P-based repair and anti-aging composition, its preparation method, and its application. Background Technology

[0002] In today's society, with increasing life expectancy and improved living standards, skin aging has become a growing concern. Therefore, the need for effective anti-aging technologies and products is increasingly urgent. This necessitates an innovative solution that meets the market's demand for anti-aging and repairing skincare products.

[0003] Existing patent 202311176187.6 discloses a complex peptide composition and its use in skin care products, comprising palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, β-alanyl hydroxyprolyl diaminobutyric acid benzylamine, chitosan, and sodium tripolyphosphate. The active ingredients are non-toxic, the preparation method is simple and easy, and the preparation conditions are mild. However, the efficacy products currently on the market have certain limitations in terms of anti-aging effects and repair, especially in terms of how to improve and repair inflammatory aging caused by neurogenic factors. Summary of the Invention

[0004] To address the problems in the prior art, the first aspect of the present invention provides a repair and anti-aging composition based on substance P (neuropeptide) to improve oily skin with inflammatory aging caused by neurotransmitters. The raw materials for its preparation include, by weight percentage, 0.00003-0.3% peptide, 0.001-0.01% artemia extract, 0.0001-0.003% plant extract, and the balance being solvent.

[0005] Preferably, the peptide includes one or more of palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, palmitoyl tripeptide-8, palmitoyl pentapeptide-4, palmitoyl tripeptide-5, palmitoyl hexapeptide-12, hexapeptide-9, and palmitoyl dipeptide-7.

[0006] Preferably, the weight ratio of palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, and palmitoyl tripeptide-8 is 0.00001-0.002: 0.00001-0.004: 0.00001-0.003.

[0007] Preferably, the weight ratio of palmitoyl tetrapeptide-7 to palmitoyl tripeptide-1 is 1:(1-3); more preferably, it is 1:2.

[0008] Preferably, the weight ratio of palmitoyl tetrapeptide-7 to palmitoyl tripeptide-8 is 1:(2-10); more preferably, it is 1:(4-9); even more preferably, it is 1:6.

[0009] In this invention, it was unexpectedly discovered that when palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, and palmitoyl tripeptide-8 were combined with other substances in a weight ratio of 2:1:6, the anti-neurogenic inflammation effect, oil-controlling effect, and penetration effect were improved. In preliminary experiments, the inventors found that adding common anti-inflammatory and oil-controlling plant extracts provided certain anti-inflammatory and oil-controlling effects. Later, when the three peptides were randomly mixed, their anti-inflammatory and oil-controlling effects were significantly increased, and the penetration effect was optimal. This may be because the structures of the three peptides are more similar to those of plant extracts, and they are lipophilic, allowing for better penetration and thus enhancing their performance.

[0010] The combination of palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, and palmitoyl tripeptide-8 in this invention has a synergistic effect, helping to balance sebum secretion in oily skin, thereby controlling facial shine and improving the overall condition of oily skin. This combination also plays a role in anti-inflammation and anti-aging, helping to reduce signs of aging caused by neurogenic inflammation. Secondly, the addition of GP4G and gardenia fruit extract enhances the overall efficacy of the skincare regimen. GP4G helps activate skin's energy metabolism and promote cell repair.

[0011] Preferably, the solvent is water.

[0012] Preferably, the Artemia extract is GP4G.

[0013] Preferably, the plant extracts include one or more of the following: Gardenia Florida fruit extract, Citrus Retucciata fruit extract, Ophiopogon japonicus root extract, Magnolia abiondii flower extract, Cladosiphon Novae-Caledoniae extract, Piper Methystucum extract, Glycyrrhiza Inflata extract, and Centella Asiatica extract.

[0014] Preferably, the weight ratio of palmitoyl tripeptide-1 to the plant extract is 1:(1-1300).

[0015] Preferably, the weight ratio of palmitoyl tripeptide-1 to gardenia fruit extract is 1:(1100-1300); more preferably, it is 1:1250.

[0016] In this invention, the addition of gardenia extract enhances the anti-inflammatory and antioxidant functions of the composition. The inventors discovered that gardenia extract contains a scientifically formulated ratio of active ingredients such as genipin and crocin, which effectively reduce the degree of skin lipid oxidation, thereby protecting the skin from damage caused by free radicals and environmental stress. This is crucial for reducing oxidative stress levels and maintaining skin health. Simultaneously, these active ingredients also possess anti-inflammatory properties, helping to alleviate inflammatory responses and reduce skin discomfort; and combined with GP4G, its unique bioactivity helps balance the skin's natural defense mechanisms, thereby enhancing its ability to resist external aggressors. Through synergistic effects with gardenia extract, the anti-inflammatory and antioxidant effects of the skincare composition are effectively amplified, providing comprehensive and powerful protection for the skin.

[0017] Preferably, the weight ratio of GP4G to palmitoyl tripeptide-8 is (1-5):1; more preferably, it is 2.5:1.

[0018] Preferably, the palmitoyl tripeptide-1 was purchased from Sederma under the trade name PALMITOYL TRIPEPTIDE-1; the palmitoyl tetrapeptide-7 was purchased from Sederma under the trade name PALMITOYL TETRAPEPTIDE-7; the palmitoyl tripeptide-8 was purchased from Vichy under the trade name PALMITOYL TRIPEPTIDE-8; and the GP4G was purchased from Ashland under the trade name Gp4g. TM pbbiofunctional; The gardenia fruit extract mentioned above was purchased from Shanghai Jinzhi Biotechnology Co., Ltd., and its trade name is GarPepair.

[0019] In this invention, specific palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, and palmitoyl tripeptide-8 are selected and combined with gardenia fruit extract and GP4G. Compared with the model control group, these compounds significantly downregulate the expression levels of the TNF-α gene to 0.344 and the iL-8 gene to 0.668, and significantly inhibit lipid content with an inhibition rate as high as 37.00%. Furthermore, in human trials, the compounds exhibit superior penetration performance compared to ordinary pig skin penetration tests. After applying the specific composition of this invention to human skin, the relative penetration rates of the active peptides (tracking peptides) were 0.52%, 1.27%, and 3.41% at 0.5h, 2h, and 4h, respectively. Other ordinary peptide products cannot achieve these performance results. The inventors have discovered that the specific combination in this invention repairs aging and damaged skin; its bioactivity helps activate the self-repair mechanism of dermal cells, promotes collagen production, thereby enhancing skin elasticity and resilience, and can also repair aging damage caused by neurogenic inflammatory response, slow down the weakening of skin elasticity, prevent collagen loss, and effectively combat aging phenomena such as facial sagging.

[0020] The second aspect of the present invention provides a method for preparing a P-based repair and anti-aging composition, wherein the P-based repair and anti-aging composition is weighed according to the weight percentage, and mixed evenly to obtain the composition.

[0021] The third aspect of this invention provides an application of a substance P-based repair and anti-aging composition for the preparation of skin care products that prevent aging caused by neurogenic inflammation.

[0022] Preferably, the skin care products include body lotion, body cream, liquid, cream, serum, lotion, shower gel, sunscreen, face mask, hand mask and foot mask.

[0023] This invention relates to a method for improving inflammation and aging in oily skin by combining a substance P repair and anti-aging composition with common skin care auxiliary materials in the field, such as skin conditioning agents, moisturizers, and functional active ingredients.

[0024] Beneficial effects

[0025] 1. In this invention, a composition for repairing and improving aging caused by neurogenic inflammation is provided by using a specific mass ratio of palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, palmitoyl tripeptide-8, GP4G and gardenia fruit extract. By controlling the proportions, it has excellent antioxidant and anti-inflammatory effects even with a small amount added.

[0026] 2. In this invention, the addition of gardenia extract enhances the anti-inflammatory and antioxidant functions of the composition, while also improving its stability against high and low temperatures.

[0027] 3. In this invention, specific palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, and palmitoyl tripeptide-8 are selected and combined with gardenia fruit extract and GP4G. Compared with the model control group, these compounds significantly downregulate the expression levels of the TNF-α gene to 0.344 and the iL-8 gene to 0.668, and significantly inhibit oil content with an inhibition rate as high as 37.00%. Furthermore, in human trials, the compounds exhibit superior penetration performance compared to ordinary pig skin penetration tests. After applying the specific composition of this invention to human skin, the relative penetration rates of the active peptides (tracking peptides) were 0.52%, 1.27%, and 3.41% at 0.5h, 2h, and 4h, respectively. Other ordinary peptide products cannot achieve these performance levels.

[0028] 4. The combination of palmitoyl tripeptide-1, palmitoyl tetrapeptide-7 and palmitoyl tripeptide-8 in this invention has a synergistic effect, which helps to balance the sebum secretion of oily skin, thereby controlling facial shine and improving the overall condition of oily skin.

[0029] 5. In this invention, it was unexpectedly discovered that when the weight ratio of palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, and palmitoyl tripeptide-8 is 2:1:6, when combined with other substances, it improves the anti-neurogenic inflammation effect, oil control effect, and penetration effect. Attached Figure Description

[0030] Figure 1 The bar chart (right) shows the relative expression levels of the tnf-α gene (left) and the iL-8 gene (right) in a zebrafish model of the anti-aging composition based on substance P prepared in Example 1.

[0031] Figure 2 The bar chart (right) shows the relative expression levels of the tnf-α gene (left) and the iL-8 gene (right) in a zebrafish model of the anti-aging composition based on substance P prepared in Example 2.

[0032] Figure 3 The bar chart (right) shows the relative expression levels of the tnf-α gene (left) and the iL-8 gene (right) in a zebrafish model of the anti-aging composition based on substance P prepared in Example 3.

[0033] Figure 4 The bar chart (right) shows the relative expression levels of the tnf-α gene (left) and the iL-8 gene (right) in a zebrafish model of the anti-aging composition based on substance P prepared in Example 4.

[0034] Figure 5 The bar chart (right) shows the relative expression levels of the tnf-α gene (left) and the iL-8 gene (right) in a zebrafish model of the anti-aging composition based on substance P prepared in Example 5.

[0035] Figure 6 The bar chart (right) shows the relative expression levels of the tnf-α gene (left) and the iL-8 gene (right) in a zebrafish model of the anti-aging composition based on substance P prepared in Example 6.

[0036] Figure 7 The bar chart (right) shows the relative expression levels of the tnf-α gene (left) and the iL-8 gene (right) in a zebrafish model of the anti-aging composition based on substance P prepared in Example 7.

[0037] Figure 8 The bar chart (right) shows the relative expression levels of the tnf-α gene (left) and the iL-8 gene (right) in a zebrafish model of the anti-aging composition based on substance P prepared in Example 8.

[0038] Figure 9The bar chart (right) shows the relative expression levels of the tnf-α gene (left) and the iL-8 gene (right) in a zebrafish model of the anti-aging composition based on substance P prepared in Example 9.

[0039] Figure 10 The bar chart (right) shows the relative expression levels of the tnf-α gene (left) and the iL-8 gene (right) in a zebrafish model of the anti-aging composition based on substance P prepared in Example 10.

[0040] Figure 11 This refers to the test objectives and test materials for the in vitro oil-controlling efficacy test of the P-based repair and anti-aging compositions prepared in Examples 1, 2, and 3.

[0041] Figure 12 This is a test method for the cytotoxicity test of the P-based repair and anti-aging compositions prepared in Examples 1, 2, and 3.

[0042] Figure 13 The results are the cytotoxicity test results of the P-based repair and anti-aging compositions prepared in Examples 1, 2, and 3.

[0043] Figure 14 This is a test method for evaluating the oil-controlling efficacy of the P-substance-based repair and anti-aging compositions prepared in Examples 1, 2, and 3.

[0044] Figure 15 The results are the oil-control efficacy test results of the P-substance-based repair and anti-aging compositions prepared in Examples 1, 2, and 3.

[0045] Figure 16 The results are the relative IOD average values ​​of the oil-controlling efficacy tests of the P-substance-based repair and anti-aging compositions prepared in Examples 1, 2, and 3.

[0046] Figure 17 The image shows the Raman spectrum of human skin before use of the P-based repair and anti-aging composition prepared in Example 1.

[0047] Figure 18 The image shows the Raman spectra of the active polypeptides in the P-based repair and anti-aging composition prepared in Example 1.

[0048] Figure 19 This image shows the distribution of peptide content at different depths of the skin over time in the P-based repair and anti-aging composition prepared in Example 1. Detailed Implementation

[0049] Example 1

[0050] This embodiment provides a substance P (neuropeptide)-based repair and anti-aging composition, which, by weight percentage, comprises 0.0001% palmitoyl tetrapeptide-7, 0.0002% palmitoyl tripeptide-1, 0.0006% palmitoyl tripeptide-8, 0.25% gardenia fruit extract, 0.0015% GP4G, and the balance being water.

[0051] This embodiment provides a method for preparing a P-based repair and anti-aging composition. The P-based repair and anti-aging composition is weighed according to the weight percentage of the P-based repair and anti-aging composition, and mixed evenly to obtain the P-based repair and anti-aging composition.

[0052] The palmitoyl tripeptide-1 was purchased from Sederma under the trade name PALMITOYL TRIPEPTIDE-1; the palmitoyl tetrapeptide-7 was purchased from Sederma under the trade name PALMITOYL TETRAPEPTIDE-7; the palmitoyl tripeptide-8 was purchased from Vichy under the trade name PALMITOYL TRIPEPTIDE-8; and the GP4G was purchased from Ashland under the trade name Gp4g. TM pbbiofunctional; The gardenia fruit extract mentioned above was purchased from Shanghai Jinzhi Biotechnology Co., Ltd., and its trade name is GarPepair.

[0053] Example 2

[0054] The specific implementation of Example 2 is the same as that of Example 1, except that the weight percentage of GP4G is 0.0036%.

[0055] The GP4G was purchased from Ashland and its trade name is Gp4g. TM pb biofunctional.

[0056] Example 3

[0057] The specific implementation of Example 3 is the same as that of Example 1, except that the weight percentage of palmitoyl tripeptide-8 is 0.0012%.

[0058] The palmitoyl tripeptide-8 was purchased from Vichy under the trade name PALMITOYL TRIPEPTIDE-8.

[0059] Example 4

[0060] Example 4 is implemented in the same manner as Example 1, except that palmitoyl tetrapeptide-7 and palmitoyl tripeptide-1 are replaced with citrus fruit extract. The weight percentage of the citrus fruit extract is 0.003%.

[0061] The citrus fruit extract was purchased from Shanghai Jiakai Biotechnology Co., Ltd., and its trade name is CalmnervCR.

[0062] Example 5

[0063] The specific implementation of Example 5 is the same as that of Example 1, except that the palmitoyl tripeptide-8 is replaced with Ophiopogon japonicus root extract; the weight percentage of the Ophiopogon japonicus root extract is 0.006%.

[0064] The Ophiopogon japonicus root extract was purchased from SILAB SA, trade name [product name missing].

[0065] Example 6

[0066] The specific implementation of Example 6 is the same as that of Example 1, except that the gardenia fruit extract is replaced with magnolia flower extract; the weight percentage of the magnolia flower extract is 0.025%.

[0067] The extract of Magnolia officinalis flower was purchased from Shanghai Jiakai Biotechnology Co., Ltd., and its trade name is Solarepare MB.

[0068] Example 7

[0069] The specific implementation of Example 7 is the same as that of Example 1, except that GP4G is replaced with Cladosporium cladosporium extract; the weight percentage of Cladosporium cladosporium extract is 0.0015%.

[0070] The extract of MysAlgae was purchased from Shanghai Huiwen Biotechnology Co., Ltd., and its trade name is MysAlgae polysaccharide.

[0071] Example 8

[0072] The specific implementation of Example 8 is the same as that of Example 1, except that the anti-aging composition based on substance P (neuropeptide) includes, by weight percentage, 0.25% gardenia fruit extract, 0.0015% GP4G and the balance water.

[0073] The GP4G was purchased from Ashland and its trade name is Gp4g. TM pb biofunctional; The gardenia fruit extract was purchased from Shanghai Jinzhi Biotechnology Co., Ltd., and its trade name is GarPepair.

[0074] Example 9

[0075] The specific implementation of Example 9 is the same as that of Example 1, except that the P-substance (neuropeptide)-based repair and anti-aging composition comprises, by weight percentage, 0.0001% palmitoyl tetrapeptide-7, 0.0002% palmitoyl tripeptide-1, 0.0006% palmitoyl tripeptide-8, 0.0015% GP4G and the balance being water.

[0076] The palmitoyl tripeptide-1 was purchased from Sederma under the trade name PALMITOYL TRIPEPTIDE-1; the palmitoyl tetrapeptide-7 was purchased from Sederma under the trade name PALMITOYL TETRAPEPTIDE-7; the palmitoyl tripeptide-8 was purchased from Vichy under the trade name PALMITOYL TRIPEPTIDE-8; and the GP4G was purchased from Ashland under the trade name Gp4g. TM pbbiofunctional.

[0077] Example 10

[0078] The specific implementation of Example 10 is the same as that of Example 1, except that the P-substance (neuropeptide)-based repair and anti-aging composition comprises, by weight percentage, 0.0001% palmitoyl tetrapeptide-7, 0.0002% palmitoyl tripeptide-1, 0.0006% palmitoyl tripeptide-8, 0.25% gardenia fruit extract, and the balance being water.

[0079] This embodiment provides a method for preparing a P-based repair and anti-aging composition. The P-based repair and anti-aging composition is weighed according to the weight percentage of the P-based repair and anti-aging composition, and mixed evenly to obtain the P-based repair and anti-aging composition.

[0080] The palmitoyl tripeptide-1 was purchased from Sederma under the trade name PALMITOYL TRIPEPTIDE-1; the palmitoyl tetrapeptide-7 was purchased from Sederma under the trade name PALMITOYL TETRAPEPTIDE-7; the palmitoyl tripeptide-8 was purchased from Vichie under the trade name PALMITOYL TRIPEPTIDE-8; and the gardenia fruit extract was purchased from Shanghai Jinzhi Biotechnology Co., Ltd. under the trade name GarPepair.

[0081] Performance testing

[0082] 1. Zebrafish Inflammatory Factor Test

[0083] System and sample size:

[0084] Experimental system: transgenic neutrophil-containing green fluorescent zebrafish (MPX).

[0085] Zebrafish age: 2 days after fertilization (2dpf).

[0086] Sample size per group: 30 tails (three biological replicates, N=3).

[0087] Adult fish rearing and breeding methods: Follow the company's laboratory standards for rearing and breeding methods, which meet the requirements of international AAALAC certification (certification number: 001458).

[0088] Mechanism of Action: Sodium dodecyl sulfate (SLS) may trigger an irritant response in the body, leading to symptoms such as edema, erythema, itching, and pain. The main phenotype of skin irritation is inflammation, with early signs including telangiectasia, increased permeability, and edema. When the irritant enters zebrafish, it induces an inflammatory response. TNF-α is the earliest and most important inflammatory cytokine to appear during the inflammatory response and can activate neutrophils. Therefore, the relative expression level of the TNF-α gene in zebrafish can be used to evaluate the soothing efficacy of the sample.

[0089] Samples: Repair and anti-aging compositions based on substance P (neuropeptide) prepared in Examples 1-10. Example 1: PBDT-1; Example 2: PBDT-2; Example 3: PBDT-3; Example 4: PBDT-4; Example 5: PBDT-5; Example 6: PBDT-6; Example 7: PBDT-7; Example 8: PBDT-8; Example 9: PBDT-9; Example 10: PBDT-10;

[0090] Experimental steps for testing the TNF-α and iL-8 genes:

[0091] 1. Randomly select zebrafish into a 6-well plate, with 30 fish per well.

[0092] 2. A zebrafish skin inflammation model was established by administering SLS in water.

[0093] 3. The sample was administered in water, with a normal control group and a model control group included. Each well contained 3 mL. Three biological replicates were performed.

[0094] Incubate at 4.28℃ in the dark for 18 hours.

[0095] 5. Total RNA was extracted from zebrafish in each experimental group, cDNA was synthesized, and the gene expression of β-actin and the target gene was detected by q-PCR.

[0096] 6. Using β-actin as an internal reference for gene expression, calculate the relative RNA expression level of the target gene.

[0097] relative RNA expression level = 2 ΔΔC(t)

[0098] ΔΔC(t)=ΔC(t) 模型对照组 -ΔC(t) 样品组

[0099] ΔC(t)=C(t) 目的基因 -C(t) β-actin

[0100] Judgment criteria: Statistical analysis showed p < 0.05, which was considered a significant difference. Results are shown in Table 1. Figure 1-10 .

[0101] Table 1

[0102]

[0103]

[0104] 2. External oil-control efficacy test

[0105] The purpose of the test and the test materials are as follows: Figure 11 .

[0106] The test method for cytotoxicity testing is described in [link to test]. Figure 12 The results of the cytotoxicity test are shown in [link to test]. Figure 13 .

[0107] The test method for oil-control efficacy testing is as follows: Figure 14 The test results for oil-control efficacy are shown below. Figure 15 , 16 Table 2.

[0108] Based on sebaceous gland cells, compared with the control group

[0109] At a concentration of 2.5% (v / v), PBDT-1 (Example 1) significantly reduced the oil content with an inhibition rate of 37.00%, indicating that the sample at this concentration could reduce the synthesis of lipid droplets in sebaceous gland cells and had an oil-controlling effect.

[0110] At a concentration of 2.5% (v / v), PBDT-2 (Example 2) significantly reduced the oil content with an inhibition rate of 29.00%, indicating that the sample at this concentration could reduce the synthesis of lipid droplets in sebaceous gland cells and had an oil-controlling effect.

[0111] At a concentration of 2.5% (v / v), PBDT-3 (Example 3) significantly reduced the oil content with an inhibition rate of 28.00%, indicating that the sample at this concentration could reduce the synthesis of lipid droplets in sebaceous gland cells and had an oil-controlling effect.

[0112] Table 2

[0113]

[0114] 3. Raman (penetration) human body test

[0115] Purpose of the test: To verify the permeability of the active ingredient in the sample during human use by measuring the penetration of the active ingredient in the human skin at 0.5h, 2h and 4h after one subject used PBDT-1, using the human (in vivo) Raman non-invasive optical test method.

[0116] Testing method: The test was conducted on a selected area at the front of the human forearm. The test product was PBDT-1. Tests were performed on 2×2 square centimeters of skin at time points of 0.5h, 2h, and 4h, and the relative penetration rate of the active ingredient after using PBDT-1 was calculated.

[0117] Test sample: PBDT-1 (the composition prepared in Example 1)

[0118] Testing instrument: LabRAM Odyssey high-speed, high-resolution microconfocal Raman spectrometer (HORIBA).

[0119] Test environment: Environmental requirements: Temperature: 22℃±2℃; Humidity: 50%RH±10%RH.

[0120] Test procedure: The test was explained to the subjects. After the subjects arrived, the test area on the inside of their arms was cleaned with water. After cleaning, the subjects sat quietly in a constant temperature and humidity room for 30 minutes. After 30 minutes, the subjects used the product according to the test requirements. In vivo Raman tests were conducted 0.5h, 2h and 4h after using the test sample.

[0121] Sample completion status: Planned enrollment: 1 person. Actual enrollment: 1 person. Number of participants completed: 1 person.

[0122] Test results:

[0123] Analysis of human skin results before product use:

[0124] The laser power used in the experiment was 2.68 mW, and the integration time at a single point was 5 s. Depth Raman imaging was performed in the XZ direction.

[0125] The data was acquired using a point-by-point scanning method, with a vertical step size of 5 μm and a scanning area of ​​20 μm × 200 μm.

[0126] The entire spectral measurement process was completed within 15 minutes. Figure 1 This is the intrinsic Raman spectrum of human skin in vivo, including the 943cm². -1 1275cm -1 1455cm -1 1655cm -1 2846cm-1 2883cm -1 934cm -1 3226cm -1 The area exhibits Raman characteristic peaks. See Figure 17 .

[0127] The assignments of Raman characteristic peaks in the skin and their representative components are shown in Table 3. The Raman spectra clearly show that the skin contains proline, hydroxyproline, glycine, proline, nucleic acids, as well as structural proteins, elastin, actin, collagen, keratin and other proteins and intercellular lipids.

[0128] Table 3

[0129]

[0130] Transdermal permeability testing of the test products:

[0131] The Raman spectra of the active polypeptide were determined experimentally. (See...) Figure 18 .

[0132] like Figure 18 As shown, the Raman characteristic peaks of active peptides are at 500 cm⁻¹. -1 790cm -1 858cm -1 1078cm -1 1294cm -1 1446cm -1 1664cm -1 2933cm -1 The characteristic peak at 1294 cm⁻¹ can be distinguished from the intrinsic peak of the skin. -1 1446cm -1 and 1664cm -1 The characteristic peaks of these three amide groups were used as representative characteristic peaks of the tested product for subsequent data processing and image tracking.

[0133] Based on the data processing results, the relative permeability of polypeptide substances in the skin at different time points is shown below. Figure 19 .

[0134] Through the Figure 19 Raman image depth analysis using PBDT-1 revealed the following distribution of active peptides at different depths in human skin after penetration: within 0.5 hours, peptides penetrated the stratum corneum; within 2 hours, peptides broke through the stratum corneum and entered the active epidermis; within 4 hours, peptides continued to penetrate the active epidermis and then into the dermis.

[0135] The relative permeability of the active peptides in each measurement area at different time points was calculated. The results were as follows: after 0.5h, 2h and 4h of PBDT-1 application to human skin, the relative permeability of the active peptides (tracking peptides) was 0.52%, 1.27% and 3.41%, respectively.

Claims

1. A P-substance-based rejuvenating composition, characterized in that, The raw materials for its preparation, by weight percentage, include 0.00003-0.3% peptides, 0.001-0.01% artichoke extract, 0.0001-0.003% plant extracts, and the balance being solvent.

2. The PEPTIDE-BASED REPAIR ANTI-AGING COMPOSITION according to claim 1, characterized in that, The peptides include one or more of palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, palmitoyl tripeptide-8, palmitoyl pentapeptide-4, palmitoyl tripeptide-5, palmitoyl hexapeptide-12, hexapeptide-9, and palmitoyl dipeptide-7.

3. The PEPTIDE-BASED REPAIR ANTI-AGING COMPOSITION according to claim 2, characterized in that, The weight ratio of palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, and palmitoyl tripeptide-8 is 0.00001-0.002: 0.00001-0.004: 0.00001-0.

003.

4. The P-substance-based repair and anti-aging composition according to claim 3, characterized in that, The weight ratio of palmitoyl tetrapeptide-7 to palmitoyl tripeptide-1 is 1:(1-3).

5. The PEPTIDE-BASED REPAIRING ANTI-AGING COMPOSITION according to claim 3, wherein The weight ratio of palmitoyl tetrapeptide-7 to palmitoyl tripeptide-8 is 1:(2-10).

6. The PEPTIDE-BASED REJUVENATION COMPOSITION of claim 2, wherein The plant extracts include one or more of the following: gardenia fruit extract, citrus fruit extract, ophiopogon root extract, magnolia flower extract, starfish tube algae extract, kava extract, licorice root extract, and centella asiatica extract.

7. The P-substance-based repair and anti-aging composition according to claim 2, characterized in that, The weight ratio of palmitoyl tripeptide-1 to plant extract is 1:(1-1300).

8. The PEPTIDE-BASED REPAIRING ANTI-AGING COMPOSITION according to claim 6, wherein The weight ratio of palmitoyl tripeptide-1 to gardenia fruit extract is 1:(1100-1300).

9. A method for preparing the anti-aging composition based on P substance according to any one of claims 1 to 8, characterized in that, Weigh the contents according to the weight percentage of the P-based repair and anti-aging composition, mix thoroughly, and the product is obtained.

10. The application of a P-substance-based repair and anti-aging composition according to any one of claims 1 to 8, characterized in that, This product is used to prepare skincare products for preventing aging caused by neurogenic inflammation; the skincare products include body lotion, body cream, liquid, cream, serum, lotion, shower gel, sunscreen, face mask, hand mask and foot mask.

Images